10-K: Kiniksa Pharmaceuticals Reports Strong 2025 Revenue Growth

Kiniksa Pharmaceuticals International, plc reported significant product revenue growth in 2025, driven by ARCALYST sales, while advancing its pipeline with KPL-387 and KPL-1161.

Summary

• Product revenue, net, increased by 62% to $677.6 million in 2025, up from $417.0 million in 2024, primarily due to increased patient enrollment for ARCALYST.
• The company achieved a net income of $59.0 million in 2025, a significant improvement from a net loss of $43.2 million in 2024.
• Cash, cash equivalents, and short-term investments totaled $414.1 million as of December 31, 2025.
• ARCALYST, approved for recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes (CAPS), and Deficiency of Interleukin-1 Receptor Antagonist (DIRA), continues to be a key commercial product.
• KPL-387, an investigational IL-1R1 antibody for recurrent pericarditis, began recruiting for its Phase 2 dose-focusing portion of the Phase 2/3 clinical trial in July 2025, with data expected in the second half of 2026.
• KPL-387 received Orphan Drug Designation from the FDA for the treatment of pericarditis in October 2025.
• KPL-1161, a pre-clinical Fc-modified IL-1R1 antibody designed for quarterly subcutaneous dosing, is expected to initiate a Phase 1 first-in-human clinical trial by the end of 2026.
• Development of abiprubart in Sjogren's Disease was discontinued in February 2025, and the company is exploring strategic alternatives for the asset.
• An ongoing technology transfer of ARCALYST drug substance manufacturing from Regeneron Pharmaceuticals, Inc. to Samsung Biologics Co., Ltd. is in progress, pending regulatory approval.
• The company completed its redomiciliation from Bermuda to the United Kingdom in June 2024.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, demonstrating strong commercial execution for ARCALYST and promising pipeline progression for KPL-387 and KPL-1161, leading to a return to profitability. However, the inherent risks of drug development, regulatory uncertainty, and reliance on third-party manufacturing temper the overall sentiment.

Positives

• Product revenue, net, increased significantly by 62% to $677.6 million in 2025, driven by strong ARCALYST sales and increased patient enrollment.
• The company returned to net profitability, reporting a net income of $59.0 million in 2025, a substantial improvement from a net loss of $43.2 million in 2024.
• Net cash provided by operating activities increased to $138.0 million in 2025, up from $25.7 million in 2024, indicating improved operational cash generation.
• KPL-387, a key pipeline asset, advanced into the Phase 2 dose-focusing portion of its Phase 2/3 clinical trial for recurrent pericarditis and received FDA Orphan Drug Designation.
• KPL-1161, a next-generation IL-1R1 antibody with potential for quarterly dosing, is progressing towards a Phase 1 first-in-human clinical trial by the end of 2026.
• The company maintains a strong liquidity position with $414.1 million in cash, cash equivalents, and short-term investments as of December 31, 2025.
• ARCALYST is seeing increased adoption and earlier prescription by healthcare professionals, supported by its status as the first and only FDA-approved therapy for recurrent pericarditis.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Negatives

• Development of abiprubart in Sjogren's Disease was discontinued in February 2025, leading to the exploration of strategic alternatives for the asset.
• Net cash used in investing activities was $189.0 million in 2025, a significant shift from net cash provided by investing activities of $37.7 million in 2024, primarily due to deploying higher levels of investable cash into longer-term treasury securities.
• Unrecognized tax benefits increased to $32.7 million in 2025 from $13.4 million in 2024, primarily related to intellectual property transfers, indicating potential future tax liabilities.

Risks

• Inability to continue commercializing ARCALYST or successfully commercialize any future products, potentially impairing revenue generation.
• Reliance on a select network of third-party specialty pharmacies for ARCALYST distribution, which may not meet the company's or patients' needs.
• Uncertainty regarding third-party payor coverage, pricing policies, and adequate reimbursement levels for current and future products.
• Difficulty in realizing benefits from price increases due to potential unfavorable actions by third-party payors.
• Uncertainty in incidence and prevalence estimates for target patient populations, potentially leading to smaller market opportunities than estimated.
• Product liability lawsuits against the company could cause substantial liabilities and limit commercialization.
• Additional regulatory burdens and other risks and uncertainties associated with future growth outside of the United States.
• Extensive healthcare regulation and enforcement by various government entities, with failure to adhere potentially having a detrimental impact on the business.
• Significant delays or failure in advancing product candidates through clinical development and obtaining regulatory approval.
• Difficulties in enrolling participants in clinical trials due to limited patient numbers, specific enrollment criteria, or competing studies.
• Undesirable side effects or adverse reactions caused by any product candidates could delay or prevent marketing approval or limit their use.
• Interim, preliminary, and top-line data from clinical trials may differ from final data, leading to potential negative impacts on approval and commercialization.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• ARCALYST and future biologic product candidates may face biosimilar competition sooner than anticipated, as ARCALYST's 12-year exclusivity for CAPS has lapsed.
• Inability to obtain or maintain the benefits associated with Orphan Drug designation, including potential market exclusivity.
• Breakthrough Therapy or Fast Track designations may not lead to a faster development or regulatory review/approval process.
• Substantial uncertainty regarding potential regulatory developments in the United States, including drug pricing and FDA oversight.
• Reliance on third parties for manufacturing commercial supply of ARCALYST and clinical supply for product candidates, increasing risks of insufficient quantities, unacceptable costs, or delays.
• The ongoing technology transfer of ARCALYST drug substance manufacturing to Samsung Biologics is subject to significant risks and uncertainties, including regulatory approval and international operational challenges.
• Sole source suppliers for drug substance and drug product for ARCALYST and KPL-387, and limited sources for abiprubart, pose supply chain risks.
• The business involves the use of hazardous materials, requiring compliance with environmental laws and regulations, which can be expensive.
• Reliance on third parties (CROs, clinical investigators) to support research activities and clinical trials, with risks of non-compliance or missed deadlines.
• Substantial competition in the biotechnology and pharmaceutical industries from companies with greater resources and expertise.
• Inability to successfully execute the growth strategy to identify, discover, develop, in-license, or acquire additional product candidates or technologies.
• Collaboration, licensing, or other strategic transactions may not be successful or on favorable terms, adversely affecting the ability to develop and commercialize products.
• Inability to adequately protect proprietary technology or obtain and maintain broad patent protection, allowing competitors to develop similar products.
• Third parties may initiate legal proceedings alleging infringement of their intellectual property rights, leading to uncertain outcomes and substantial costs.
• Inability to effectively enforce intellectual property rights throughout the world, especially in jurisdictions with weaker protection.
• Changes to patent laws in the United States and other jurisdictions could diminish the value of patents.
• Inability to protect the confidentiality of trade secrets, harming the business and competitive position.
• History of operating losses and potential requirement for substantial additional financing in the future.
• Failure to comply with reporting and payment obligations under government pricing and price reporting programs could lead to penalties or sanctions.
• Current and future healthcare legislation or executive/administrative action may have a material adverse effect on the business and results of operations.
• Information technology systems, or those of third-party contractors, may fail or suffer cyberattacks or security incidents.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws could adversely affect the business.
• Future success depends on the ability to retain key executives and senior management, and attract/motivate qualified personnel.
• Employees, principal investigators, CROs, consultants, and other third-party service providers may engage in misconduct or improper activities.
• Changes in United States trade policy, including tariffs, could materially impact the business and results of operations.
• Unfavorable global economic or operational conditions could adversely affect the business.
• Climate change and related regulation may result in increased costs or negatively impact operations.
• Concentration of ownership of Class B ordinary shares and conversion rights of Class A1 and B1 ordinary shares may influence corporate decisions and affect Class A ordinary share price.
• Increased shareholder voting requirements in the UK relative to the United States may limit flexibility in issuing new shares.
• Difficulty for United States investors to enforce civil liabilities against the company due to English law incorporation.
• Potential for unanticipated tax liabilities, including from reallocation of taxable income among subsidiaries.
• Potential classification as a Passive Foreign Investment Company (PFIC) for United States federal income tax purposes, leading to adverse tax consequences for U.S. Holders.

Future Outlook

The company expects its existing cash balance and anticipated cash inflows from ARCALYST sales to fund operating expenses and capital expenditure requirements for at least the next 12 months. It anticipates requiring additional capital if it pursues further collaboration, licensing, or strategic transactions. Data from the Phase 2 portion of the KPL-387 trial in recurrent pericarditis is expected in the second half of 2026, which will guide further development strategy. A Phase 1 first-in-human clinical trial for KPL-1161 is planned by the end of 2026. Strategic alternatives for abiprubart are being explored. The company does not expect current United States tariffs to materially impact its overall business. New EU pharmaceutical rules, agreed in December 2025, are expected to modernize the regulatory landscape, offering 8 years of data protection and 1 year of market protection for new medicines, with potential extensions up to 11 years.

Management Comments

• "We believe that advancing KPL-387 through the clinic and into the market will further our mission of meeting patients needs."
• "We believe that each of our product candidates holds the potential to offer differentiated therapy to patients, and we aim to unlock that potential through innovative research and development."
• "We put patients first and live by our motto: Every Second Counts."
• "We believe that our commitment to compliance, quality and ethics throughout our business makes us a stronger and more competitive organization."

Industry Context

StockSavvy.ai notes that Kiniksa's strong ARCALYST sales and pipeline advancements in IL-1 inhibition therapies align with the growing focus on targeted immunomodulation for inflammatory diseases. The discontinuation of abiprubart in Sjogren's Disease reflects the high-risk nature of drug development, where companies often re-prioritize assets based on clinical data and market potential. The ongoing technology transfer to Samsung Biologics highlights the industry trend of leveraging global CDMOs for manufacturing, while also exposing the company to geopolitical and supply chain risks. The company's focus on recurrent pericarditis, a rare cardiovascular disease, positions it within the orphan drug market, which often benefits from specific regulatory incentives and less direct competition for approved therapies.

Comparison to Industry Standards

• ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis, establishing it as a market leader in this specific indication.
• The American College of Cardiology Concise Clinical Guidance prioritized IL-1 inhibition therapy as a second-line treatment for auto-inflammatory phenotype pericarditis, reflecting growing acceptance of ARCALYST's therapeutic class.
• KPL-387 aims to offer monthly subcutaneous self-administration, potentially providing a more convenient dosing method compared to ARCALYST's weekly subcutaneous dosing and oral therapies in development like Cardiol Therapeutics' CardiolRx (Phase 3) and Ventyx Biosciences' VTX2735 (Phase 2) for recurrent pericarditis.
• KPL-1161 is designed for quarterly subcutaneous dosing, which would represent a significant convenience improvement over current and developing therapies, potentially differentiating it from competitors in the IL-1 inhibition space.
• Abiprubart's high-concentration subcutaneous formulation for monthly dosing was previously considered a key differentiator against other CD40/CD154 pathway antagonists such as Amgen's Dazodalibep, Sanofi's frexalimab, and Biogen/UCB's dapirolizumab pegol, before its development was discontinued.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal proceedings.

Related Party Transactions

• Entities affiliated with certain of the company's directors hold Class A1 and Class B1 ordinary shares, which have conversion rights that could significantly increase their voting control (up to approximately 74% of aggregate voting power on an as-converted basis).
• Dr. Richard S. Levy, a director, entered into a Consulting Agreement with Kiniksa Pharmaceuticals, GmbH, effective January 1, 2026, to provide advice on pipeline development strategy and clinical trial protocols, receiving cash and Restricted Stock Units as compensation.

Stakeholder Impact

• **Shareholders**: Positive impact from increased revenue and return to profitability. Potential for dilution from future equity raises. Share price volatility due to market conditions and intellectual property disputes. Concentration of voting power may limit influence of new investors.
• **Patients**: Continued commercialization of ARCALYST provides treatment for recurrent pericarditis, CAPS, and DIRA. KPL-387 and KPL-1161 offer potential new, more convenient treatment options for recurrent pericarditis. Discontinuation of abiprubart development means no new treatment for Sjogren's Disease from Kiniksa.
• **Employees**: Benefit from competitive pay, comprehensive benefits, and equity awards. The company's focus on ethics, compliance, and health/safety aims to foster a positive work environment. Future success is dependent on the ability to attract, retain, and motivate qualified personnel.
• **Suppliers/CDMOs**: Continued reliance on third-party manufacturers (Regeneron, Samsung Biologics) and Contract Research Organizations (CROs). The technology transfer to Samsung creates new risks and opportunities for manufacturing partners.
• **Creditors**: Improved financial health, evidenced by net income and positive cash flow from operations, may reduce perceived credit risk.

Next Steps

• Determine further development strategy for KPL-387 based on Phase 2 data expected in the second half of 2026.
• Initiate a Phase 1 first-in-human clinical trial of KPL-1161 by the end of 2026.
• Explore strategic alternatives for abiprubart.
• Continue to execute on ARCALYST commercialization, expanding awareness and market.
• Complete the technology transfer of ARCALYST drug substance manufacturing to Samsung Biologics and obtain regulatory approval for the facility.
• Continue collaborative study agreement with The Mayo Clinic (and Johns Hopkins University) to investigate ARCALYST in cardiac sarcoidosis.
• Monitor and adapt to evolving healthcare legislation and regulatory changes, including drug pricing reforms and data protection laws.
• Continue internal discovery activities to identify new wholly-owned molecules.
• Evaluate opportunities to partner or out-license programs.

Key Dates

Recommendation

The company demonstrated strong commercial execution for ARCALYST, leading to a substantial 62% increase in product revenue and a return to net profitability in 2025. The pipeline shows promising advancements with KPL-387 entering Phase 2/3 trials and receiving Orphan Drug Designation, and KPL-1161 progressing towards Phase 1. While the discontinuation of abiprubart is a setback, the overall financial performance and strategic focus on high-potential assets in cardiovascular indications suggest a positive trajectory for growth and value creation. The healthy cash position provides a solid foundation for ongoing development and commercialization efforts.

Keywords

Biopharmaceutical, recurrent pericarditis, ARCALYST, IL-1 inhibition, KPL-387, KPL-1161, orphan drug, clinical trials, drug development, SEC filing, 10-K, financial results, corporate governance, risk factors, pharmaceutical, biotechnology, autoimmune diseases, cardiovascular diseases, Samsung Biologics, Regeneron